Prelude Therapeutics Incorporated

NASDAQ PRLD Stock
Profitability for 1 year: +204.63%
Dividend yield: 0%
Sector: Healthcare

Company Analysis Prelude Therapeutics Incorporated

Download the report: word Word pdf PDF

1. Summary

Advantages

  • The stock's return over the last year (204.63%) is higher than the sector average (0.6%).
  • Current debt level 10.27% is below 100% and has decreased over 5 years from 29964.22%.

Disadvantages

  • Price (3.29 $) is higher than fair price (1.6 $)
  • Dividends (0%) are below the sector average (0.55%).
  • The company's current efficiency (ROE=-69.01%) is lower than the sector average (ROE=102.4%)

Similar companies

ABIOMED

Alexion

Gilead Sciences

Amgen

2. Share price and performance

2.1. Share price

2.3. Market efficiency

Prelude Therapeutics Incorporated Healthcare Index
7 days 18.3% 7.2% -1.5%
90 days 50.2% -8.6% 0.7%
1 year 204.6% 0.6% 13.2%

PRLD vs Sector: Prelude Therapeutics Incorporated has outperformed the "Healthcare" sector by 204.03% over the past year.

PRLD vs Market: Prelude Therapeutics Incorporated has outperformed the market by 191.43% over the past year.

Stable price: PRLD is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.

Long period: PRLD with weekly volatility of 3.94% over the past year.

3. Summary of the report

3.1. General

P/E: -0.5
P/S: 13.81
More data on PRLD

3.2. Revenue

EPS -1.68
ROE -69.01%
ROA -56.12%
ROIC -38.49%
Ebitda margin -1995.91%
More data on PRLD

5. Fundamental Analysis

5.1. Stock price and price forecast

The fair price is calculated taking into account the Central Bank refinancing rate and earnings per share (EPS)

Above fair price: The current price (3.29 $) is higher than the fair price (1.6 $).

Price is higher than fair: The current price (3.29 $) is 51.4% higher than the fair price.

5.2. P/E

P/E vs Sector: The company's P/E (-0.5) is lower than that of the sector as a whole (29.98).

P/E vs Market: The company's P/E (-0.5) is higher than that of the market as a whole (-87.32).

5.3. P/BV

P/BV vs Sector: The company's P/BV (0.74) is lower than that of the sector as a whole (249.13).

P/BV vs Market: The company's P/BV (0.74) is lower than that of the market as a whole (82.22).

5.3.1 P/BV Similar companies

5.5. P/S

P/S vs Sector: The company's P/S indicator (13.81) is lower than that of the sector as a whole (127.74).

P/S vs Market: The company's P/S indicator (13.81) is lower than that of the market as a whole (115.2).

5.5.1 P/S Similar companies

5.5. EV/Ebitda

EV/Ebitda vs Sector: The company's EV/Ebitda (-0.73) is higher than that of the sector as a whole (-23.82).

EV/Ebitda vs Market: The company's EV/Ebitda (-0.73) is higher than that of the market as a whole (-82.75).

6. Profitability

6.1. Profitability and revenue

6.2. Earnings per share - EPS

6.3. Past profitability Net Income

Yield Trend: Rising and has grown by 2.96% over the last 5 years.

Earnings Slowdown: The last year's return (0%) is below the 5-year average return (2.96%).

Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (172.16%).

6.4. ROE

ROE vs Sector: The company's ROE (-69.01%) is lower than that of the sector as a whole (102.4%).

ROE vs Market: The company's ROE (-69.01%) is lower than that of the market as a whole (-6.94%).

6.6. ROA

ROA vs Sector: The company's ROA (-56.12%) is lower than that of the sector as a whole (-1.94%).

ROA vs Market: The company's ROA (-56.12%) is lower than that of the market as a whole (37.49%).

6.6. ROIC

ROIC vs Sector: The company's ROIC (-38.49%) is lower than that of the sector as a whole (0.7%).

ROIC vs Market: The company's ROIC (-38.49%) is lower than that of the market as a whole (9.35%).

Pay for your subscription

More functionality and data for company and portfolio analysis is available by subscription

Subscribe

7. Finance

7.1. Assets and debt

Debt level: (10.27%) is quite low in relation to assets.

Debt reduction: over 5 years, the debt has decreased from 29964.22% to 10.27%.

Excess of debt: The debt is not covered by net income, percentage -14.17%.

7.2. Profit growth and share price

8. Dividends

8.1. Dividend yield vs Market

Low yield: The dividend yield of the company 0% is below the average for the sector '0.55%.

8.2. Stability and increase in payments

Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.

Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.

8.3. Payout percentage

Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.

9. Insider trades

9.1. Insider trading

Insider Buying Exceeds insider sales by 100% over the last 3 months.

9.2. Latest transactions

Transaction date Insider Type Price Volume Quantity
02.09.2021 Pierce Christopher
EVP and Chief of Business Oper		 Sale 41.68 708 560 17 000
02.09.2021 Pierce Christopher
EVP and Chief of Business Oper		 Purchase 12.85 218 450 17 000